BPC 157

Product Details

BPC 157 Peptide (Body Protection Compound 157) — Research Grade Peptide, ≥98% Purity (HPLC)

Synthetic pentadecapeptide. Lyophilized powder. Lot-specific COA included.

BPC 157 Peptide is a synthetic 15-amino acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (H-GEPPPGKPADDAGLV-OH). The compound is derived from a partial sequence of human gastric juice protein and is characterized as a cytoprotective agent in the research literature. It is classified as a stable gastric pentadecapeptide with high resistance to enzymatic degradation.

The peptide’s research profile centers on its modulation of angiogenesis and the nitric oxide (NO) system. Preclinical studies indicate that BPC-157 upregulates endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor A (VEGF-A) expression while counteracting oxidative stress markers such as malondialdehyde (MDA).

A separate line of mechanistic research has identified an interaction between BPC-157 and the E3 ubiquitin ligase adaptor protein FBXO22, which suppresses the ubiquitination and proteasomal degradation of the transcription factor BACH1 — a pathway implicated in angiogenesis regulation. BPC 157 Peptide

Supplied as a sterile-filtered, lyophilized powder for in vitro and preclinical research applications. Each lot is independently verified for purity and identity and ships with a Certificate of Analysis.

Specifications

Note: BPC-157 is supplied in both free base and acetate salt forms. The FDA has documented that supplier COAs for the acetate form often report the free base CAS number and molecular weight despite the product being the acetate salt.

Verify the exact form and molecular weight against the Certificate of Analysis supplied with your lot. BPC 157 Peptide

Research applications

BPC 157 Peptide is used in laboratory settings to investigate:

• Angiogenesis and vascular signaling — modulation of VEGFR2 signaling, FAK-paxillin pathways, and FBXO22-dependent stabilization of BACH1 in endothelial cell models

• Nitric oxide system research — upregulation of NOS1-3 isoforms, modulation of NO levels, and counteraction of oxidative stress in animal models of tissue injury

• Tendon, ligament, and muscle injury models — cytoprotective effects in osteotendinous, myotendinous, and muscle-to-bone junction research, administered systemically or locally without carrier proteins

• Corneal healing research — maintenance of corneal transparency and resolution of corneal angiogenic privilege in preclinical models

• Neurodegenerative disease models — counteraction of Parkinson’s disease-like and Alzheimer’s disease-like disturbances in rodent models, with effects linked to NO-system modulation

• Gastrointestinal cytoprotection — the compound’s originating research context, involving gastric mucosal protection and organoprotection

Handling and storage

Reconstitute under aseptic conditions using sterile water or an appropriate aqueous buffer. BPC-157 is soluble in water at 100 mg/mL and in DMSO at 50 mg/mL; moisture-contaminated DMSO may reduce solubility. Add solvent slowly down the vial wall rather than directly onto the lyophilized powder, and swirl gently to dissolve. Do not shake or vortex, as this can cause aggregation. BPC 157 Peptide

Lyophilized powder is stable for several years at −20 °C or below, desiccated and protected from light. Reconstituted solutions should be stored at 2–8 °C and are typically stable for 2–4 weeks. Aliquot reconstituted solution to avoid repeated freeze-thaw cycles. For long-term storage of reconstituted solution, store below −18 °C and consider adding a carrier protein (0.1% HSA or BSA).  BPC-157 powder

For laboratory use by qualified personnel only.